Agilent Technologies Unveils Groundbreaking Innovations and Structural Transformation at SLAS2025 in San Diego
SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A), a stalwart in the advancement of scientific and technological solutions, will be presenting its latest automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition, set to take place from January 25-29 at the San Diego Convention Center, California. This event marks a pivotal moment for Agilent as it continues to solidify its position as a leader in providing comprehensive solutions for optimizing laboratory performance, enhancing efficiency, and ensuring reproducibility across the continuum of laboratory processes from research and drug discovery to development.
The spotlight on Agilent at SLAS2025 is a testament to the company s relentless pursuit to serve the burgeoning needs of modern laboratories through automation. The new automated workflow solutions are designed to seamlessly integrate with existing systems, thereby enabling laboratories to operate with heightened precision and confidence. By leveraging state-of-the-art technology, Agilent aims to empower their client laboratories to achieve unprecedented levels of operational excellence and throughput while maintaining strict adherence to regulatory standards.
In parallel with this major technological unveiling, Agilent celebrates a significant milestone in the regulatory landscape with the approval of its PD-L1 IHC 28-8 pharmDx companion diagnostic assay. This Class C assay, now certified under the European In Vitro Diagnostic Regulation (IVDR), was previously marked as CE-IVD for sales across the European Union. This certification underscores Agilent’s commitment to delivering reliable diagnostic solutions that meet the stringent requirements of the evolving regulatory environment.
PD-L1 IHC 28-8 pharmDx is designed for exclusive use with the Agilent Autostainer, providing a robust tool for pathology labs to assess PD-L1 protein expression in oncology, thereby playing a crucial role in guiding immunotherapy decisions. This precise alignment with regulatory bodies further enhances Agilent s portfolio in the critical field of personalized medicine, where the need for accurate and timely diagnostics is paramount.
Simultaneously, Agilent is announcing a transformative shift in its organizational structure aimed at fostering a market-focused, customer-centric strategy. This new structural alignment, effective immediately, is envisioned to drive accelerated growth and operational agility. By restructuring leadership roles and operational divisions, Agilent is set to advance its capabilities to better meet the dynamic demands of its customer base.
The introduction of our new organizational framework is an essential step in our journey to becoming a more nimble company, remarked Agilent President and CEO, Pad. By placing our customers and markets at the heart of our operations, we aim to enhance our responsiveness and effectiveness in addressing the ever-evolving challenges they face.
In conclusion, Agilent Technologies is poised to make a notable impact at SLAS2025 with its cutting-edge automated laboratory solutions and strategic organizational enhancements. These initiatives, when combined, demonstrate Agilent s unwavering commitment to innovation, regulatory compliance, and customer-centric growth as it navigates the challenges and opportunities of the future laboratory landscape.
Comments